Clinical trials: Insulinoma, open to volunteers
Insulinoma; Pancreas
Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma
Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies.
- Trial name
- EUSRFAINSU (NCT07585032)
- Testing
- EUS-RFA
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Sahlgrenska University Hospital
Insulinoma; Pancreas, MEN1
Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions
The goal of this observational study is to evaluate the long-term clinical effectiveness of EUS-RFA and quality of life in patients with pancreatic or adrenal tumors recieving EUS-RFA.
- Conditions
- Insulinoma; Pancreas, MEN1, NETs, Radiofrequency Ablation
- Trial name
- EURAGIL (NCT07272187)
- Testing
- observational study
- Where
- Denmark
- Volunteers
- 138 people
- Sponsor
- Herlev Hospital
Hypoglycemia, Insulinoma
Diagnosing and Treating Low Blood Sugar Levels
Hypoglycemia is the term used to refer to lower than normal levels of blood sugar. This study will continue to research the causes of hypoglycemia.
- Trial name
- NCT00001276
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Congenital Hyperinsulinism, Insulinoma
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
Low blood sugars are known to cause brain damage in newborn babies. One of the most common causes of low blood sugars persisting beyond the new born period is a condition called congenital hyperinsulinism (HI).
- Trial name
- NCT02021604
- Testing
- Fluorodopa F 18
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Cook Children's Health Care System
Hyperinsulinism
Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism
The purpose of the study is to provide access to 18F-DOPA PET to patients at Washington University and assess the utility of 18F-DOPA PET/MRI as a preoperative tool to detect and localize focal lesions in the pancreas that are…
- Trial name
- 18FDOPA HI (NCT05088798)
- Testing
- 18F-Fluoro Dopa PET/MRI Imaging
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Washington University School of Medicine
Insulinoma
Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma Localization
This clinical research evaluates a new PET/CT imaging agent, [68Ga]Ga-HBED-CC-PEG6-exendin-4, for localizing insulinoma, a rare pancreatic tumor that causes severe low blood sugar.
- Trial name
- HBED-CC-PEG6-E (NCT07808879)
- Testing
- [68Ga]Ga-HBED-CC-PEG6-exendin-4 PET/CT, [68Ga]Ga-HBED-CC-exendin-4 PET/CT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
GLP1-R-related Disease, Tumor
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
To evaluate the potential usefulness of 68Ga/18F-Exendin 4 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.
- Conditions
- GLP1-R-related Disease, Tumor, Insulinoma, Positron Emission Tomography
- Trial name
- NCT06725693
- Testing
- 18F/68Ga-Exendin 4
- Where
- 3 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Tumor Hyperinsulinism (Tumor HI)
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
- Trial name
- Tumor HI (NCT06881992)
- Testing
- Ersodetug
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 16 people
- Sponsor
- Rezolute